Cite
HARVARD Citation
Lanzafame, M. et al. (n.d.). Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient. International journal of STD & AIDS. pp. 726-728. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Lanzafame, M. et al. (n.d.). Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient. International journal of STD & AIDS. pp. 726-728. [Online].